Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

10.17650/1726-9776-2012-8-1-14-22

LECTURE

ЛЕКЦИЯ

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER

ВНУТРИПУЗЫРНАЯ БЦЖ-ТЕРАПИЯ ПРИ МЫШЕЧНО-НЕИНВАЗИВНОМ РАКЕ МОЧЕВОГО ПУЗЫРЯ

Figurin

K. M.

Фигурин

К. М.

Russian Federation

kfigurin@mail.ru

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва

30032012

14222507201425072014

https://oncourology.abvpress.ru/oncur/article/view/74

The paper considers the state-of-the-art of BCG vaccine treatment for non-muscle invasive bladder cancer. It gives data on the meta-analyses of foreign studies of the efficiency of BCG therapy in this pathology.

Рассмотрено современное состояние проблемы лечения мышечно-неинвазивного рака мочевого пузыря с использованием вакцины БЦЖ. Приведены данные метаанализов зарубежных исследований по изучению эффективности применения БЦЖ-терапии при данной патологии.

non-muscle invasive bladder cancervaccineintravesical BCG theraefficiencyadverse events

мышечно-неинвазивный рак мочевого пузырявакцина БЦЖвнутрипузырная БЦЖ-терапияэффективностьпобочные явления

1. Morales A., Eidinger D., Bruce A. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180−3.

Morales A., Eidinger D., Bruce A. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180−3.

2. Witjes W.P., Witjes J.A., Oosterhof G.O., Debruyne M.J. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTa-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urology Group. Semin Urol Oncol 1996;14(Supp 1): 10−6.

Witjes W.P., Witjes J.A., Oosterhof G.O., Debruyne M.J. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTa-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urology Group. Semin Urol Oncol 1996;14(Supp 1): 10−6.

3. Sylvester R.J., van der Meijden A.P.M., Lamm D.L. Intravesical Bacillus Calmette-

Sylvester R.J., van der Meijden A.P.M., Lamm D.L. Intravesical Bacillus Calmette-

Guerin reduces the risk of progression in patient with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964−70.

4. Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216−23.

Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216−23.

5. Thalmann G.N., Birkhaeuser F., Rentsch C.A. et al. Bacillus Calmette-Guerin (BCG) used for intravesical in the treatment of nonmuscle invasive transitional cell carcinoma (TCC) of the bladder:Does the strain matter? Eur Urol Suppl 2007;6(2): 61.

Thalmann G.N., Birkhaeuser F., Rentsch C.A. et al. Bacillus Calmette-Guerin (BCG) used for intravesical in the treatment of nonmuscle invasive transitional cell carcinoma (TCC) of the bladder:Does the strain matter? Eur Urol Suppl 2007;6(2): 61.

6. Suttmann H., Riemensberger J., Bentien G. et al. Neutrophil granulocytes are required for effective Bacillus Calmettee-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006;66:8250−7.

Suttmann H., Riemensberger J., Bentien G. et al. Neutrophil granulocytes are required for effective Bacillus Calmettee-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006;66:8250−7.

7. Brandau S., Riemensberger J., Jacobsen M. et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001;92:697−702.

Brandau S., Riemensberger J., Jacobsen M. et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001;92:697−702.

8. Martinez-Pineiro J.A., Solsona E., Rodriguez R.H. et al. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and TIS bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174(4, part 1):1242−7.

Martinez-Pineiro J.A., Solsona E., Rodriguez R.H. et al. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and TIS bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174(4, part 1):1242−7.

10.

9. Ojea A., Nogueira J.L., Solsona E. et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: lowdose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13,5 mg) versus mitomycin C. Eur Urol 2007;52(5):1398−406.

Ojea A., Nogueira J.L., Solsona E. et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: lowdose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13,5 mg) versus mitomycin C. Eur Urol 2007;52(5):1398−406.

11.

10. Unda M., Madero R., Solsona E. et al. Long-term follow up of the effectiveness of

Unda M., Madero R., Solsona E. et al. Long-term follow up of the effectiveness of

12.

standard dose BCG (81 mg. connaught strain) comparing with a three fold reduce dose (27 mg.) in high risk non muscle invasive bladder cancer. CUETO group. Eur Urol Suppl 2009;8(4):No 655.

13.

11. Fernandez-Gomez J., Solsona E., Unda M. et al. Prognostic factors in patients with nonmuscle-invasive bladder cancer treated withbacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992−1002.

Fernandez-Gomez J., Solsona E., Unda M. et al. Prognostic factors in patients with nonmuscle-invasive bladder cancer treated withbacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992−1002.

14.

12. Bassi P., Spinadin R., Carando R. et al. Modified induction course: a solution to sideeffects? Europ Urol 2000; 37 (Suppl. 1):31−2.

Bassi P., Spinadin R., Carando R. et al. Modified induction course: a solution to sideeffects? Europ Urol 2000; 37 (Suppl. 1):31−2.

15.

13. Andius P., Fehrling M., Holmang S. Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 2005;96(9):1290–3.

Andius P., Fehrling M., Holmang S. Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 2005;96(9):1290–3.

16.

14. Lamm D.L. Preventing progression and improving survival with BCG maintenance. Europ Urol 2000;37 (Suppl. 1):9–15.

Lamm D.L. Preventing progression and improving survival with BCG maintenance. Europ Urol 2000;37 (Suppl. 1):9–15.

17.

15. Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1): 90−5.

Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1): 90−5.

18.

16. Bohle A., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63:682–7.

Bohle A., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63:682–7.

19.

17. Malmstrom P.-U., Sylvester R.J., Crawford D.E. et al. An individual patients data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56(2):247−56.

Malmstrom P.-U., Sylvester R.J., Crawford D.E. et al. An individual patients data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56(2):247−56.

20.

18. Martinez-Pineiro L., Hernandez R., Zabala J.A. et al. Maintenance bacillus Calmette-Guerin immunotherapy for TaG3 or T1G3 and/or carcinoma in situ transitional cell carcinoma of the bladder: a randomised CUETO Group study. Eur Urol Suppl 2008;7(3):298, abstr 08.

Martinez-Pineiro L., Hernandez R., Zabala J.A. et al. Maintenance bacillus Calmette-Guerin immunotherapy for TaG3 or T1G3 and/or carcinoma in situ transitional cell carcinoma of the bladder: a randomised CUETO Group study. Eur Urol Suppl 2008;7(3):298, abstr 08.

21.

19. Lamm D., Persad R., Colombel M., Brausi M. Vaintenance bacillus Calmette-Guerin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol Suppl 2010;9:715−34.

Lamm D., Persad R., Colombel M., Brausi M. Vaintenance bacillus Calmette-Guerin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol Suppl 2010;9:715−34.

22.

20. Babjuk M., Oosterlinck W., Sylvester R. et al. European Association of Urology. Pocket Guidelines 2011 edition. Guidelines on non-muscle invasive bladder cancer. P 7–20.

Babjuk M., Oosterlinck W., Sylvester R. et al. European Association of Urology. Pocket Guidelines 2011 edition. Guidelines on non-muscle invasive bladder cancer. P 7–20.

23.

21. Jarvinen R., Kaasinen E., Sankila A. et al. Longterm Efficacy of Maintenance Bacillus Calmette-Gueґrin Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up. Eur Urol 2009;56(2):260–5.

Jarvinen R., Kaasinen E., Sankila A. et al. Longterm Efficacy of Maintenance Bacillus Calmette-Gueґrin Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up. Eur Urol 2009;56(2):260–5.

24.

22. Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate and high risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57(5):766−73.

Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate and high risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57(5):766−73.

25.

23. Hall M.C., Chang S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314−30.

Hall M.C., Chang S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314−30.

26.

24. Sylvester R., Van der Meijden A.,Witjes J.A., Kurth K. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: a metaanalysis of the published results of randomized clinical trials. Eur Urol Suppl 2005;4(3):219. No 866.

Sylvester R., Van der Meijden A.,Witjes J.A., Kurth K. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: a metaanalysis of the published results of randomized clinical trials. Eur Urol Suppl 2005;4(3):219. No 866.

27.

25. Gardmark T., Jahnson S., Wahlquist R. et al. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 2007;99(4):817−20.

Gardmark T., Jahnson S., Wahlquist R. et al. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 2007;99(4):817−20.

28.

26. Duchek M., Johansson R., Jahnson S. et al. Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon- 2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57:25−31.

Duchek M., Johansson R., Jahnson S. et al. Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon- 2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57:25−31.

29.

27. Shelley M.D., Wilt T.J., Court J. et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumor recurrence in highrisk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485−90.

Shelley M.D., Wilt T.J., Court J. et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumor recurrence in highrisk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485−90.

30.

28. Oosterlinck W., Kirkali Z., Sylvester R.J. et al. Sequential chemo-immunotherapy with Mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder. Results of EORTC GU Group randomized phase II study 30993. Eur Urol Suppl 2010;9(2):91, abstr 189.

Oosterlinck W., Kirkali Z., Sylvester R.J. et al. Sequential chemo-immunotherapy with Mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder. Results of EORTC GU Group randomized phase II study 30993. Eur Urol Suppl 2010;9(2):91, abstr 189.

31.

29. Moutzouris G., Lykourinas M., Malovrouvas D. et al. Prospective, randomized, comparative study of high dose intravesical epirubicin versus BCG for prophylaxis in intermediate risk superficial bladder tumors. Eur Urol Suppl 2007;6(2):171.

Moutzouris G., Lykourinas M., Malovrouvas D. et al. Prospective, randomized, comparative study of high dose intravesical epirubicin versus BCG for prophylaxis in intermediate risk superficial bladder tumors. Eur Urol Suppl 2007;6(2):171.

32.

30. Friedrich M.G., Pichlmeier U., Schwaibold H. et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52(4): 1123−30.

Friedrich M.G., Pichlmeier U., Schwaibold H. et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52(4): 1123−30.

33.

31. Gallagher B.L., Joudi F.N., Maymi J.L., O’Donnell M.A.. Impact of Previous Bacille Calmette-Guerin Failure Pattern on Subsequent Response to Bacille Calmette-Guerin Plus Interferon Intravesical Therapy. Urology 2008; 71:297–301.

Gallagher B.L., Joudi F.N., Maymi J.L., O’Donnell M.A.. Impact of Previous Bacille Calmette-Guerin Failure Pattern on Subsequent Response to Bacille Calmette-Guerin Plus Interferon Intravesical Therapy. Urology 2008; 71:297–301.

34.

32. Kaasinen E., Wijkstrom H., Malmstrom P.-U. et al. Alternating Mitomycin C and BCG instillations alone versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Europ Urol 2003;43:637−45.

Kaasinen E., Wijkstrom H., Malmstrom P.-U. et al. Alternating Mitomycin C and BCG instillations alone versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Europ Urol 2003;43:637−45.

35.

33. Droller M.J. Urothelial tumors. American cancer society. Atlas of clinical oncology. 2004 BC Decker Inc Hamilton. London.

Droller M.J. Urothelial tumors. American cancer society. Atlas of clinical oncology. 2004 BC Decker Inc Hamilton. London.

36.

34. Van der Meijden A.P., Sylvester R.J., Oosterlinck W. et al. EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429–34.

Van der Meijden A.P., Sylvester R.J., Oosterlinck W. et al. EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429–34.

37.

35. Rischmann P., Colombei M., Saint F. et al. Prophylactic ofloxacine to improve tolerance of BCG intravesical instillations: a randomized prospective, double-blind, placebo-controlled, multicentre study in patients with mid to high risk superficial bladder tumours. Eur Urol Suppl 2005;4(3):219. No 868.

Rischmann P., Colombei M., Saint F. et al. Prophylactic ofloxacine to improve tolerance of BCG intravesical instillations: a randomized prospective, double-blind, placebo-controlled, multicentre study in patients with mid to high risk superficial bladder tumours. Eur Urol Suppl 2005;4(3):219. No 868.

38.

36. Autorino R., De Sio M., Perdona S. et al. shortterm administration of prulifloxacin represent a reasonable strategy in the prevention of intravesical bcg-induced to xicity? Eur Urol Suppl 2009; 8(4):283No 650.

Autorino R., De Sio M., Perdona S. et al. shortterm administration of prulifloxacin represent a reasonable strategy in the prevention of intravesical bcg-induced to xicity? Eur Urol Suppl 2009; 8(4):283No 650.

39.

37. Serretta V., Ruggirello A., Scuto F. et al. Can single dose prulifloxacin improve patients’ compliance to bacillus Calmette-Guerin intravesical therapy? Eur Urol Suppl 2010;9(2):92, abstr 191.

Serretta V., Ruggirello A., Scuto F. et al. Can single dose prulifloxacin improve patients’ compliance to bacillus Calmette-Guerin intravesical therapy? Eur Urol Suppl 2010;9(2):92, abstr 191.

40.

38. Persad R., Lamm D., Brausi M. et al. Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur Urol Suppl 2008;7(10):637−50.

Persad R., Lamm D., Brausi M. et al. Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur Urol Suppl 2008;7(10):637−50.

41.

39. Lockyer C.R.W., Sedgwick J.E.C., Gillat D.A. Beware the BCG failures: a rewiew of one institution,s results. Eur Urol 20024;42:542−6.

Lockyer C.R.W., Sedgwick J.E.C., Gillat D.A. Beware the BCG failures: a rewiew of one institution,s results. Eur Urol 20024;42:542−6.

42.

40. Gattegno B. T1G3 Bladder Cancer: Conservative Management or Cystectomy?

Gattegno B. T1G3 Bladder Cancer: Conservative Management or Cystectomy?

43.

Eur Urol 2004;45:399–400.

44.

41. Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166(4):1296–9.

Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166(4):1296–9.

45.

42. Herr H.W., Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169:1706−8.

Herr H.W., Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169:1706−8.

46.

43. Skinner E.C. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol. Oncol 2007;25:523−5.

Skinner E.C. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol. Oncol 2007;25:523−5.

47.

44. Witjes A. Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance? Urol Oncol 2009;27:322–4.

Witjes A. Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance? Urol Oncol 2009;27:322–4.

48.

45. Brian L. Gallagher, Fadi N. et al. Impact of previous Bacille Calmette-Guerin failure pattern on subsequent response to Bacille Calmette-Guerin plus interferon intravesical therapy. Urology 2008; 71:297–301.

Brian L. Gallagher, Fadi N. et al. Impact of previous Bacille Calmette-Guerin failure pattern on subsequent response to Bacille Calmette-Guerin plus interferon intravesical therapy. Urology 2008; 71:297–301.

49.

46. Lee C.T., Montie J.E., Zhang Y.X. et al. Lymphovascular invasion is an independent predictor of survival in cT1 bladder cancer. J Urol 2005;173(4):246, abstr 911. AUA Annual Meeting, Program Abstracts. San Antonio. AUA 2005. May 21−26, abstr № 911.

Lee C.T., Montie J.E., Zhang Y.X. et al. Lymphovascular invasion is an independent predictor of survival in cT1 bladder cancer. J Urol 2005;173(4):246, abstr 911. AUA Annual Meeting, Program Abstracts. San Antonio. AUA 2005. May 21−26, abstr № 911.

50.

47. Denzinger S., Fritsche H-M., Otto W. et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008;52(1):146−52.

Denzinger S., Fritsche H-M., Otto W. et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008;52(1):146−52.

51.

48. Masood S., Sriprasad S., Palmer J.H. et al. T1G3 bladder cancer — indications for early cystectomy. Int Urol Nephrol 2004;36;41–4.

Masood S., Sriprasad S., Palmer J.H. et al. T1G3 bladder cancer — indications for early cystectomy. Int Urol Nephrol 2004;36;41–4.

52.

49. Malavaud B. T1G3 Bladder Tumours: The case for radical cystectomy. Eur Urol 2004;45:406–10.

Malavaud B. T1G3 Bladder Tumours: The case for radical cystectomy. Eur Urol 2004;45:406–10.

53.

50. Palou J., Gaya J.M., Sylvester R. et al. Prognostic factors for recurrence and progression in T1G3 bladder cancer treated with BCG: CIS in the prostatic urethra and gender. Eur Urol Suppl 2009;8(4):285. No 658.

Palou J., Gaya J.M., Sylvester R. et al. Prognostic factors for recurrence and progression in T1G3 bladder cancer treated with BCG: CIS in the prostatic urethra and gender. Eur Urol Suppl 2009;8(4):285. No 658.

54.

51. Montesino-Semper M., Madero-Jarabo R., Solsona-Narbon E. et al. Treatment of carcinoma in situ of the bladder associated or not associated to non-muscle invasive transitional carcinoma using two different BCG doses: The standard or one-third dose. A five year follow-up. Eur Urol Suppl 2010;9(2):9, abstr 188.

Montesino-Semper M., Madero-Jarabo R., Solsona-Narbon E. et al. Treatment of carcinoma in situ of the bladder associated or not associated to non-muscle invasive transitional carcinoma using two different BCG doses: The standard or one-third dose. A five year follow-up. Eur Urol Suppl 2010;9(2):9, abstr 188.

55.

52. Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Effect of age on treatment outcome and tol erance in patients with stage Ta T1 papillary carcinoma of the bladder treated with maintenance bacillus Calmette-Guerin: Results of EORTC GU Group study 30911. Eur Urol Suppl 2009;8(4):285. No 659.

Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Effect of age on treatment outcome and tol erance in patients with stage Ta T1 papillary carcinoma of the bladder treated with maintenance bacillus Calmette-Guerin: Results of EORTC GU Group study 30911. Eur Urol Suppl 2009;8(4):285. No 659.